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Abstract
Background: A pancreatoduodenectomy (PD) is a highly advanced procedure associated with
considerable post-operative complications and substantial costs. In this study the hospital costs asso-
ciated with complications after PD were assessed.
Methods: A retrospective cohort study was conducted on 100 consecutive patients who underwent a
pylorus-preserving (PP)PD between January 2012 and July 2013. Per patient, all complications occur-
ring during admission or in the 30-day period after discharge were documented. All hospital costs
related to the (PP)PD were defined as the costs of all medical interventions and resources during the
hospitalisation period as recorded by the electronic supply tracking system.
Results: The median hospital costs ranged from €17 482 for a patient without complications to
€55 623 for a patient with a post-operative haemorrhage. A post-operative haemorrhage was associ-
ated with a 39.6% increase in total hospital costs after adjusting for patient characteristics. Other fac-
tors significantly associated with an increase in total hospital costs were: the presence of a malignancy
other than a pancreatic adenocarcinoma (29.4% cost increase), the severity grade of a complication
(34.3–70.6% increase) and the presence of a post-operative infection (32.4% increase).
Conclusions: This study provides an in-depth analysis of hospital costs and identifies factors that are
associated with substantial cost consequences of specific complications occurring after a PD.
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Introduction
Health care costs are rising worldwide and, therefore, cost con-
tainment is one of the most important challenges in future medi-
cine. Health care expenditures are considered to be at least in
part influenced by the aging population, but the increase of per-
forming specialised surgical procedures also contributes to high
hospital costs.1–3 Post-operative complications also substantially
increase the use of additional resources per patient and prolong
the hospital stay, raising medical costs even further.4–8
A pancreatoduodenectomy (PD) is a typical example of a
complex, highly specialised surgical procedure. Despite a
reduction in the mortality of PD below 5% in high-volume
centres, a PD is still accompanied with a substantial morbidity
and post-operative complication rates are varying between 40
and 60%.9–12 Important surgical complications after PD
include anastomotic leakage, in particular of the pancreatojej-
unostomy and leading to a pancreatic fistula (PF), haemor-
rhage and delayed gastric emptying (DGE).13–15
Reducing complications has become a desirable goal for
quality improvement initiatives to optimise patient outcomes
and to reduce hospital costs.16–18 Previous studies have already
identified factors that can predict post-operative complications.
Examples of such predictors are duodenal or ampullary lesions
that generally present with a non-dilated pancreatic duct and a
soft pancreas, which more frequently result in leakage of the
pancreatic anastomosis, pancreatic fistula and a subsequently
higher risk of a post-operative haemorrhage, but also pre-oper-
ative nausea, which is associated with a higher incidence of
DGE and a prolonged hospital stay.19,20
Although patients at risk of developing complications after a
PD can be identified, limited information is currently available
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about costs of specific complications.21 An in-depth cost evalu-
ation of pancreatic surgery, in particular regarding procedures
with and without specific complications, might gain insight
into the economic burden of those complications. This could
be helpful to predict hospital costs after pancreatic surgery.
Information about hospital costs might also be helpful to sug-
gest changes in the management of complications with the aim
of reducing health care expenditures.
The aim of this study was, therefore, to quantify the cost
consequences of complications occurring in hospitalised
patients after a PD. Furthermore, we assessed which factors are
associated with an increase in total hospital costs.
Patients and methods
Study design
A retrospective cohort study was conducted at a tertiary-refer-
ral university hospital in the Netherlands. This is a retrospec-
tive review of a database with real-time data capture. Data on
a consecutive series of adult patients who underwent a PPPD
or classic PD between January 2012 and July 2013 were pro-
spectively included in this database. Patients with metastasis or
local non-resectable disease during exploration were not
included in this study. Data gathered during this 1.5-year
observation period included the minimum follow-up period of
30 days after discharge.
The following clinical data were included: age, gender, co-
morbidities, American Society of Anesthesiologists (ASA) clas-
sification, type of PD, the need for a vascular resection, (histo)
pathologic diagnosis, length of hospital stay, readmissions,
reoperations and the length of intensive care unit (ICU) stay.
We used the STROBE statement to ensure the proper
reporting of this observational study.22
Complications
All complications as documented in a local database of the
Dutch National Surgical Complication Registry (Landelijke
Heelkundige Complicatie Registratie, LHCR) were analysed.
The LHCR was developed by the Dutch Society of Surgeons
and is a slightly modified version of the Clavien–Dindo classifi-
cation.23,24 The following definition of a complication was used
in the registry and this study: ‘an unintended and undesired
outcome or state occurring during or following medical care
that is so harmful to the patients’ health that it requires
(adjustment of) treatment or leads to permanent damage’.25
Variables registered in the complication registry comprise
patient characteristics, admission characteristics and complica-
tions occurring during admission or in the 30-day period after
discharge leading to readmission, reoperation, or death.
All complications reported during morning handovers with
the attendance of the complete surgical staff and residents are
encoded in this registration, as well as complications reported
in the discharge letter. The reliability of this complication data-
base was independently audited.26
The complication registry categorises each complication into
four grades of severity: Grade 1, temporary health disadvantage
recovering without reoperation (grade 1 management includes
radiological or endoscopic interventions; similar to Dindo grade
I, II and IIIa); grade 2, recovery after reoperation (similar to
Dindo grade IIIb); grade 3, (probably) permanent damage or
function loss (similar to Dindo grade IV when permanent); and
grade 4, death (similar to Dindo grade V). Patients were
followed until their complication had recovered, or it was
obvious that the complication resulted in permanent damage or
death. When multiple complications were reported in one
patient, the recorded level of severity was determined by the
most severe complication. Minor complications, such as an elec-
trolyte imbalance or fever, even without clinical consequences,
were also registered in the LHCR database and were classified as
severity grade 1.
Furthermore, the complication registry was searched by two
investigators independently (T.B.S. and A.V.) to select three
important and specific complications for pancreatic surgery,
i.e. ‘post-operative haemorrhage’, ‘anastomotic leakage’ and
‘DGE’. If DGE occurred without postoperative haemorrhage or
an anastomotic site leakage, the complication was labelled
as ‘isolated DGE’. If a patient had a combination of post-
operative haemorrhage and anastomotic leakage, the patient
was analysed in both of these complication groups. If the type
of complication was unclear based on the complication regis-
try, the investigators checked the information from the dis-
charge letter and the (electronic) medical record. Discrepancies
between investigators were resolved by discussion. Admission
to the ICU is not part of standard post-operative care after a
PD and patients are only admitted to the ICU in case of severe
complications.
Costs
We included all hospital costs per patient, including outpatient
visits and readmissions that were directly related to the
provided care in relation to the PD. Costs related to the diag-
nostic pathway before the operation and additional costs of
non-related diagnoses or procedures in the past were not taken
into account.
Electronic supply tracking allowed accurate determination of
hospital costs for a specific diagnosis and were provided by the
financial department of the hospital. Unit costs for a specific
product included the front-office costs of personnel (e.g.
nurses, surgeons), material use, as well as the back-office costs
of facility and overhead. In our hospital, all specialists (sur-
geons) are employed by the hospital with a fixed yearly salary.
Total hospital costs per patient were calculated as the
product-sum of volumes and unit costs of care and were sub-
divided into seven cost domains: ‘general diagnostics’ (e.g. lab-
oratory, microbiology and pathology investigations), ‘imaging’
(e.g. CT or MRI scans), ‘outpatient clinic’ (e.g. visits to outpa-
tient clinic or emergency department), ‘clinical care’ (ward care
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and 1-day hospital admissions), ‘surgical’ (operating room and
surgical supplies), ‘ICU’ (critical care) and ‘other costs’. The
cost domain ‘other costs’ included costs for blood transfusion,
percutaneous drainage and similar procedures.
Incurred hospital costs in the period before the PD were not
taken into account, because of the wide variety of diagnostic
pathways prior to surgery, partly performed in other hospitals.
The time horizon of the study was restricted to the index
admission and readmissions for the treatment of complications
within 30 days of initial hospital discharge. Considering the
limited time horizon, no discounting of costs took place to
account for time preference. Unit costs were expressed for the
base year 2014. Only in-hospital costs were included in this
study. Costs for additional care, such as nursing facilities or
home care, were not included in this study.
Statistical analysis
Statistical analyses were performed using Statistical Package for
the Social Sciences version 21 (SPSS Inc., Armonk, NY, USA).
Descriptive statistics were expressed as means and standard
deviations, or medians and inter-quartile ranges (IQR), when-
ever appropriate. Risk differences were calculated and pre-
sented with 95% confidence intervals (CI). Student’s t and
Mann–Whitney U-tests were used to analyse differences
between two groups with normally or non-normally distrib-
uted continuous variables (such as costs), respectively. The chi-
square test was used to compare percentages (e.g. patient char-
acteristics) and the Kruskal–Wallis test was used to compare
more than two non-normally distributed groups (e.g. the three
specific complications chosen for further analysis). Kaplan–
Meier estimates of total hospital costs were obtained and com-
pared with three patient groups (without complications, with
grade 1 complications, and with grade 2 complications), using
log-rank test statistics. The level of significance was defined as
a P-value less than 0.05.
Univariable and stepwise multivariable linear regression was
used to explore possible associations between specific patient
characteristics and total costs. Log-transformation of the
dependent variable ‘total costs’ was performed because of
its non-linear distribution. Categorical variables (e.g. post-
operative diagnosis, complication severity) were recoded into
dummy variables before analysing the data. Possible predic-
tors were entered in the multivariable analysis when showing
a (nearly) significant (i.e. P < 0.10) difference between
patients with and without complications according to the
univariable linear regression analysis. Results from the regres-
sion analyses are expressed as regression coefficients, 95% CI
and P-values.
Results
Between January 2012 and July 2013, 100 consecutive adult
patients underwent a PD and were included in this study. The
mean age at surgery was 64.0  10.0 years and most patients
were males (59%). Eighty-five of the patients underwent a
PPPD; the remaining patients underwent standard PD. None
of the included patients received pre-operative chemo(radio)
therapy.
Overall, 73% of the patients sustained one or more compli-
cations. Of the three selected complications, anastomotic leak-
age (PJ, HJ, GJ) was the most common (24/100). Isolated DGE
and a post-operative haemorrhage were reported less frequently
(in 18 and 12 patients, respectively). In eight of the latter
patients, leakage and a post-operative haemorrhage occurred
simultaneously. Mortality during admission and in the 30-day
period after discharge was 1%. Unplanned readmission within
30 days after discharge was required in 10 patients (10%) with
a grade 1 complication and in one patient (1%) with a grade 2
complication.
Characteristics of patients with and without a complication
are summarised in Table 1. Patients with complications after
surgery more frequently showed a history of cardiac disease
and hospital- and ICU stay in this group were significantly
longer.
There were no significant differences in age, gender, ASA
classification, type of surgical treatment and post-operative
diagnosis between the groups without or with one or more
complications.
Costs related to the occurrence of a complication
The median total hospital costs per patient were €25 047 (IQR
18 430–44 600), whereas the mean total hospital costs were
€37 416 (SD 29 814).
Having selected the most severe complication for each
patient, 58/73 (79.5%) complications were classified as sever-
ity grade 1 (without reoperation), 13/73 (17.8%) as severity
grade 2 (with reoperation), one (1/73; 1.4%) as grade 3 (per-
manent damage or function loss), and one as grade 4 (death).
Table 2 presents a comparison of hospital costs among
patients without complications, those with a grade 1 or a
grade 2 complication. The Kaplan–Meier curves for the three
study groups are shown in Fig. 1. The difference between the
cost curves was statistically significant (log-rank test, P <
0.001). In a small proportion of patients, grade 1 and 2 com-
plications caused an increase in the total hospital costs up to
€150 000.
Patients with a grade 2 complication had significantly higher
hospital costs (P-values ranged from <0.005 to 0.012; data not
shown) than patients with a grade 1 complication in all
domains except for the domains ‘general diagnostics’, ‘imaging’
and ‘outpatient clinic’. They also had a significantly longer
hospital stay than those with grade 1 complications (medians
29 versus 14 days, respectively; P = 0.002). This was also true
for the length of ICU stay (1 versus 0 days, respectively; P =
0.004). Patients with a grade 1 complication had a higher ASA
classification (P = 0.007) and more often a history of heart dis-
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Table 1 Characteristics of patients without or with one or more complications after a pancreatoduodenectomy
No complication
N = 27
With ≥ 1 complication
N = 73
RD or MD (95% CI) P-value
Age at surgery in years (SD) 64.2 (11.9) 64.0 (9.3) MD 0.2 (4.3 to 4.7) 0.105
Gender (%)
Male 15 (55.6) 44 (60.3) RD 0.047 (0.257 to 0.157) 0.670
Type of resection (%)
Pylorus-preserving PD 23 (85.2) 62 (84.9) RD 0.003 (0.186 to 0.136) 0.975
ASA classification (%)
I 6 (22.2) 16 (21.9) 0.434
II 20 (74.1) 48 (65.8)
III/IV 1 (3.7) 9 (12.3)
Comorbidity (%)
Cardiac disease 0 (0.0) 12 (16.4) RD 0.164 (0.266 to 0.223) 0.025
Pulmonary disease 2 (7.4) 5 (6.8) RD 0.006 (0.092 to 0.170) 0.923
Diabetes 7 (25.9) 14 (19.2) RD 0.068 (0.098 to 0.269) 0.462
Hypertension 10 (37.0) 19 (26.0) RD 0.110 (0.098 to 0.318) 0.281
Histologic diagnosis (%)
Pancreatic adenocarcinoma 10 (37.0) 22 (30.1) 0.314
Ampullary adenocarcinoma 2 (7.4) 6 (8.2)
Distal CBD adenocarcinoma 5 (18.5) 16 (21.9)
Other (pre)malignanta 6 (22.2) 26 (35.6)
Other benign 4 (14.8) 3 (4.1)
Vascular resection (%) 3 (11.1) 7 (9.6) 0.822
Median length of hospital stay
in days (IQR)
8 (7–10 15 (10–26) <0.001
Median length of ICU stay in days (IQR) 0 (0–0) 0 (0–1†) 0.005
Severity of complications (%)
Grade 1 58 (79.5)
Grade 2 13 (17.8)
Grade 3 1 (1.4)
Grade 4 1 (1.4)
Number of complications (%)
1 28 (38.4)
2 19 (26.0)
3 10 (13.7)
4 6 (8.2)
≥5 10 (13,7)
Type of complication (%)
Post-operative haemorrhage 12 (16.4)
Anastomotic leakage 24 (32.9)
Isolated delayed gastric emptying 18 (24.7)
Post-operative infection
(local or systemic)
33 (45.2)
ASA, American Society of Anaesthesiologists; CBD, common bile duct; IQR, interquartile range; MD, mean difference; PD, pancreatoduodenecto-
my; RD, risk difference; SD, standard deviation; CI, confidence interval.
Italic values indicate the significance level of P <0.05
aOther (pre)malignant: e.g. multiple endocrine neoplasia in the pancreatic head area or duodenal carcinoma.
†Range 0–33 days.
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ease (P = <0.001) than patients with grade 2 complications.
There were no differences in other comorbidity, age, gender,
type of surgical treatment and post-operative diagnosis
between the two severity groups (data not shown).
Costs of common complications
Hospital costs of the three selected complications, anastomotic
site leakage, isolated DGE and post-operative haemorrhage, are
summarised in Table 3.
Anastomotic leakage occurred in 24/100 patients. In eight
cases, this was in combination with a late post-operative haem-
orrhage. Patients with an anastomotic leakage had a median
length of hospital stay of 26 days (IQR 15–36 days) and 0 days
ICU stay (IQR 0–4; range 0–33). There was no need for reop-
eration in 54.2% of the patients with an anastomotic leakage
(N = 13), and accordingly these were classified as severity
grade 1. Nine patients were classified as severity grade 2
(37.5%), and one patient was classified as having a grade 3
complication (because this patient needed a permanent ileosto-
my due to the complication). One patient died after an anasto-
motic leakage in combination with a late post-operative
haemorrhage (grade 4). The median total hospital costs for a
patient with an anastomotic leakage were €53 760, more than
three times the total hospital costs of a patient without compli-
cations.
Patients with isolated DGE (occurring in 18/100 patients, all
classified as grade 1) had a median length of hospital stay of
14 days (IQR 10–25) and 0 days ICU stay (IQR 0–0; range
0–4). The median total hospital costs for a patient with an
isolated DGE were €26 825, which was only half of the costs
for a patient with anastomotic leakage, but still more than
50% higher than the median total hospital costs of €17 482 for
a patient without complications.
Table 2 Analysis of costs (in Euros) for patients without and with a grade 1 or grade 2 complication after a pancreatoduodenectomy
Median costs (IQR) No complication
N = 27
Grade 1 complication
N = 58
Grade 2 complication
N = 13
P-value*
Total costs 17 482 15 831–20 800 28 380 21 182–46278 57 060 40 641–90 454 <0.001
General diagnostics 1869 1630–2590 3363 2299–4990 4731 3978–7195 <0.001
Imaging 166 0–658 764 434–2502 2051 1033–4068 <0.001
Outpatient clinic 1211 880–2144 1325 928–2289 1950 800–2661 0.610
Clinical care 4975 4422–6634 10 504 7608–15 380 17 690 14 373–36 077 <0.001
ICU 0 0–0 0 0–0b 3950 0–7684 <0.001
Surgical 7772 7772–7772a 7772 7772–7772c 14 527 8674–18 530 0.002
Other costs 942 658–1.537 1917 1015–7589 6220 4640–20 131 <0.001
IQR, Inter-quartile Range.
Italic values indicate the significance level of P <0.05
aRange € 3683–€ 15 544; bRange € 0–€ 42 646; cRange € 3683–43 032, *Kruskal–Wallis test.
Total hospital costs (in Euros)
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Figure 1 Kaplan–Meier curves of the proportion of patients
without a complication or with a grade 1 or grade 2 complication
and their total hospital costs
Figure 2 Median costs per domain by the occurrence of a specific
complication after a pancreatoduodenectomy
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A post-operative haemorrhage was reported in 12/100 patie-
nts. As mentioned before, in eight patients this was in combina-
tion with anastomotic leakage. In patients with a post-operative
haemorrhage, the median length of hospital stay was 23 days
(IQR 13–39 days) and 3 days ICU stay (IQR 0–5 days). There
was no need for reoperation in five patients (5/12; 41.7%; sever-
ity grade 1) and five patients were classified as severity grade 2
(6/12; 50.0%). The median total hospital costs for a patient with
a post-operative haemorrhage were €55 623.
The median hospital costs in the different domains for each
of these three specific complications versus the median costs
for patients without a complication are summarised in Fig. 2.
Clinical care and surgical costs contributed mostly to the total
hospital costs of complications.
When comparing the costs domains in patients with a post-
operative haemorrhage and anastomotic leakage, none of the
domains showed statistically significant differences (P-values
ranged from 0.164 to 0.830). Compared with patients with an
isolated DGE, the cost domains ‘total costs’, ‘ICU’ and ‘other
costs’ were significantly higher in the group with a post-opera-
tive haemorrhage (P-values 0.004, 0.003, 0.001, respectively)
and anastomotic leakage (P-values 0.035, 0.006, 0.003, respec-
tively).
Regression analyses
Results of the univariable and multivariable linear regression
analyses are shown in Table 4. Significant predictors of total
hospital costs were a histological diagnosis, complication sever-
ity, post-operative haemorrhage, anastomotic site leakage and
the presence of a post-operative infection. A post-operative
haemorrhage was associated with a 39.6% increase in total hos-
pital costs. For an average patient, the total hospital costs
increased with €11 485 if a post-operative haemorrhage
occurred (increase from €28 973 to €40 458). The presence of
a malignancy other than a pancreatic adenocarcinoma (e.g.
duodenum carcinoma) was also associated with higher total
hospital costs (29.4% increase). Furthermore, the occurrence of
a grade 1 (34.3% increase) or a grade 2–4 (70.6% increase)
complication and the presence of a post-operative infection
(32.4% increase) were associated with higher hospital costs.
This model explained almost 50% (R2 = 0.479) of the variance
in the total hospital costs.
Discussion
This study showed that the total hospitals cost after a PD dou-
ble if a complication occurs. In the case of a complication
requiring a re-operation to recover, the total hospital costs
even triple. Furthermore, the occurrence of a post-operative
haemorrhage is independently associated with a 39.6% cost
increase, mainly owing to the increased hospital stay. Numer-
ous ways to reduce the length of hospital stay are currently
described.27,28 Length of hospital stay can be influenced by
implementing specific protocols or programmes or through
cooperation with other hospitals and skilled nursing facili-
ties.29,30 Prevention and early diagnosis of complications could
also contribute to a reduction of the length of hospital stay by
the implementation of the several evidence-based bundles for
post-operative wound infection, pneumonia or sepsis.31
Additionally, we found that high hospital costs after a PD
are associated with diagnosis, severity grade of a complication
and the presence of a post-operative infection. A diagnosis
other than a pancreatic adenocarcinoma, for example multiple
endocrine neoplasia (MEN) in the pancreatic head area, duo-
denal carcinoma or suspected adenomas most of whom were
likely to have had a ‘soft pancreas’ because there was no
obstruction of the pancreatic duct, was a predictor of high
hospital costs. In a soft pancreas, the management of compli-
cations is usually more difficult and consists of more expensive
diagnostic procedures and interventions.
Table 3 Analysis of costs (in Euros) of the three most common complications after a pancreatoduodenectomy
Median costs (IQR) Post-operative
haemorrhage
N = 12/100
Anastomotic leakage
N = 24/100
Isolated DGE
N = 18/100
P-value*
Total costs 55 623 35 825–101489 53 760 24 449–90 577 26 825 22 179–39 461 0.016
General diagnostics 5203 3398–9092 4655 3023–9092 3907 2606–5555 0.468
Imaging 2121 783–3791 1577 729–3791 680 328–2882 0.109
Outpatient clinic 1370 786–1900 1370 762–2382 1386 890 –1952 0.885
Clinical care 14 307 12 310–35 700 17 171 9674–30 748 12 162 7601–15 064 0.117
ICU 5709 988–11 555 3950 0–7793 0 0–0a 0.002
Surgical 12 885 7365–15 113 8674 7772–14.426 7772 7772–7772b 0.270
Other costs 10 298 7589–23 098 6476 1880–10 913 1288 776–2788 <0.001
Italic values indicate the significance level of P <0.05
IQR, interquartile range.
aRange € 0–€ 9660.
bRange € 3683–€ 24 567.
*Kruskal–Wallis test.
HPB 2015, 17, 723–731 ª 2015 International Hepato-Pancreato-Biliary Association
728 HPB
As a possibly feasible option in the future management of
complications we recommend first optimal and early diagnostic
work-up in patients with clinical post-operative problems;
second, if complications are diagnosed, early intervention by
non-operative procedures, because these are less costly than
operative interventions and showed no differences in the success
rates in a previous study and will lead to a shorter hospital stay.32
Age and ASA classification did not seem to be associated
with hospital costs. This is in contrast with other studies show-
ing that these pre-operatively identifiable factors are associated
with an increased risk for a complication especially with age
> 70–75 years or an ASA classification of II or higher.33–37
These discrepancies could be attributed to the selection of
patients for PD. Only patients in a good pre-operative perfor-
mance state were accepted for surgery, and they were not
excluded only based on age. This selection of patients is
reflected in the fact that few patients classified as ASA III/IV
(10%) were included in this study. A recent study supported
Table 4 Univariable and multivariable analyses of possible factors predicting total costs
Univariable analysis Multivariable analysis
Ratio for
cost increase
95% CI P-value Ratio for
cost
increase
95% CI P-value
Age 0.996 0.984–1.009 0.568
Gender 0.873 0.680–1.119 0.279
Operation procedure
PPPD vs. standard PD 0.882 0.626–1.244 0.471
ASA classification
ASA I RC
ASA II 0.894 0.661–1.209 0.462
ASA III/IV 0.772 0.608–1.556 0.906
Histological diagnosis
Pancreatic adenocarcinoma RC RC
Ampullary adenocarcinoma 0.992 0.627–1.570 0.973 0.902 0.624–1.319 0.584
Distal CBD adenocarcinoma 1.419 1.024–1.966 0.036 1.130 0.622–1.493 0.381
Other (pre)malignanta 1.610 1.203–2.153 0.002 1.294 1.019– 1.644 0.035
Other benign 0.919 0.566–1.491 0.730 0.881 0.585–1.324 0.538
Vascular resection 0.760 0.506–1.140 0.183
Complication severity
No complication RC RC
Grade 1 1.723 1.355–2.190 <0.001 1.343 1.050–1.714 0.019
Grade 2, 3 or 4 2.849 2.061–3.940 <0.001 1.706 1.167–2.495 0.006
Readmission within 30 days 1.300 0.881–1.917 0.184
Post-operative haemorrhage 2.163 1.531–3.055 <0.001 1.396 1.002–1.950 0.049
Anastomotic leakage 1.892 1.462–2.449 <0.001 1.253 0.957–1.637 0.099
Delayed gastric emptying 1.203 0.887–1.632 0.231
Post-operative Infection
(local or systemic)
1.833 0.887–2.394 <0.001 1.324 1.057–1.660 0.015
Co morbidity
Heart diseaseb 1.133 0.777–1.652 0.513
Pulmonary diseasec 1.057 0.653–1.710 0.820
Diabetes 0.932 0.690–1.261 0.647
Hypertension 0.879 0.672–1.151 0.346
ASA, American Society of Anesthesiologists; CBD, common bile duct; RC, reference category; PD, pancreatoduodenectomy; PPPD, pylorus-pre-
serving pancreatoduodenectomy; CI, confidence interval.
aOther (pre)malignant: e.g. multiple endocrine neoplasia in the pancreatic head area or duodenal carcinoma.
b
Including a history of angina pectoris, heart failure, myocardial infarction or an arrhythmia.
cIncluding a history of asthma, chronic obstructive pulmonary disease (COPD) or pulmonary tuberculosis.
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our findings and also showed no association between age and
morbidity after a PD.38
Because complications result in high hospital costs, it is
obvious that cost savings could be achieved by reducing the
incidence of complications after a PD. However, it remains diffi-
cult to act upon the presence of predicting factors for complica-
tions. In this study, predicting factors such as malnutrition and
pre-operative cholangitis were not taken into account because
the decision to perform surgery is based on other medical
grounds and cholangitis was treated pre-operatively by antibiot-
ics and drainage. Therefore, selection could have influenced the
outcome of these predicting factors.
Previous studies showed the relationship between high hos-
pital-volume and surgeon-volume on a lower incidence of
complications and quality of care.11,39–41 It seems fair to say
that cost savings can be achieved nation-wide by performing
pancreatic surgery only in high-volume hospitals and by expe-
rienced surgeons.21
The overall complication rate in the present study was higher
than in previous reports from our hospital as well as from other
contemporary studies despite a 1% mortality.9–12 This is most
likely because the patient sample from the present study contains
mostly patients with a diagnosis different than pancreatic adeno-
carcinoma leading to more complications. Furthermore, a
broader definition of a complication was used in this study, and
various resources were checked to track all complications that
had occurred.26 The registry also includes mild complications,
such as a slight electrolyte imbalance without any clinical conse-
quence or any form of delirium after surgery.
Some limitations to our study are worth mentioning. First,
the data obtained were from consecutive patients from a sin-
gle tertiary university hospital during an 18-month admission
period. Therefore, the generalisability regarding costs to other
hospitals or time periods is unclear. However, currently the
majority of (PP)PD procedures is performed in high-volume
tertiary referral hospitals. Second, we derived the costs of
complications by top-down comparing hospital costs in dif-
ferent patient groups rather than directly attributing bottom-
up which hospital resources were spent on the management
of each complication. Third, we have tried to include only
the hospital costs that were directly related to the PD. How-
ever, it is possible that we missed some hospital costs because
they seemed not directly related (e.g. visits to the ophthal-
mology outpatient clinic) to the PD but might have been in
reality, or vice versa. It is not likely this would have influ-
enced our results and conclusions substantially because these
additional hospital costs will be only minor. Fourth, we did
not have follow-up data on potential complication-related
readmissions that took place in a hospital elsewhere. How-
ever, their number would be low or even zero, because
patients who underwent a PD are well informed about possi-
ble post-operative complications and the importance of
returning to the index hospital.
Conclusion
By providing an in-depth analysis of hospital costs owing to
complications after pancreatic surgery, the impact of complica-
tions expressed as costs are identified and clarified. With this
knowledge, we can and will advocate further efforts to reduce
hospital costs by shortening the length of hospital stay by
implementing specific protocols or programmes or through
cooperation with other hospitals and skilled nursing facilities.
Inherently, efforts should be made to reduce the cost by mak-
ing efforts to prevent complications and reduce the length of
stay, not only to facilitate cost containment in surgical care
but also to improve the quality of patient care.
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